

Sacituzumab govitecan-hziy ASCENT

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Sacituzumab govitecan-hziy ASCENT

FINAL SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Treatment of patients with unresectable or metastatic TNBC who have received ≥ 2 prior systemic therapies, ≥ 1 of them for advanced disease
 Experimental Arm: Sacituzumab govitecan-hziy
 Control Arm: Physician's choice of single agent ChT

